Causal modelling of variation in clinical practice and long-term outcomes of ADHD using Norwegian registry data: The ADHD controversy project by Mykletun, Arnstein et al.
1Mykletun A, et al. BMJ Open 2021;11:e041698. doi:10.1136/bmjopen-2020-041698
Open access 
Causal modelling of variation in clinical 
practice and long- term outcomes of 
ADHD using Norwegian registry data: 
the ADHD controversy project
Arnstein Mykletun   ,1,2,3,4 Tarjei Widding- Havneraas,2,5 Ashmita Chaulagain,2,5 
Ingvild Lyhmann,2,5 Ingvar Bjelland,5,6 Anne Halmøy,5,6 Felix Elwert,7 
Peter Butterworth,8 Simen Markussen,9 Henrik Daae Zachrisson,10 Knut Rypdal2
To cite: Mykletun A, Widding- 
Havneraas T, Chaulagain A, 
et al.  Causal modelling of 
variation in clinical practice 
and long- term outcomes 
of ADHD using Norwegian 
registry data: the ADHD 
controversy project. BMJ Open 
2021;11:e041698. doi:10.1136/
bmjopen-2020-041698
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
041698).
Received 17 June 2020
Revised 30 November 2020
Accepted 21 December 2020
For numbered affiliations see 
end of article.
Correspondence to
Professor Arnstein Mykletun;  
 arnstein. mykletun@ uit. no
Protocol
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Introduction Attention- deficit/hyperactivity disorder 
(ADHD) is among the most common mental disorders in 
children and adolescents, and it is a strong risk factor for 
several adverse psychosocial outcomes over the lifespan. 
There are large between- country and within- country 
variations in diagnosis and medication rates. Due to ethical 
and practical considerations, a few studies have examined 
the effects of receiving a diagnosis, and there is a lack of 
research on effects of medication on long- term outcomes.
Our project has four aims organised in four work 
packages: (WP1) To examine the prognosis of ADHD (with 
and without medication) compared with patients with 
other psychiatric diagnoses, patients in contact with public 
sector child and adolescent psychiatric outpatient clinics 
(without diagnosis) and the general population; (WP2) 
Examine within- country variation in ADHD diagnoses and 
medication rates by clinics’ catchment area; and(WP3) 
Identify causal effects of being diagnosed with ADHD and 
(WP4) ADHD medication on long- term outcomes.
Method and analysis Our project links several 
nationwide Norwegian registries. The patient sample is all 
persons aged 5–18 years that were in contact with public 
sector child and adolescent psychiatric outpatient clinics 
in 2009–2011. Our comparative analysis of prognosis will 
be based on survival analysis and mixed- effects models. 
Our analysis of variation will apply mixed- effects models 
and generalised linear models. We have two identification 
strategies for the effect of being diagnosed with ADHD 
and of receiving medication on long- term outcomes. Both 
strategies rely on using preference- based instrumental 
variables, which in our project are based on provider 
preferences for ADHD diagnosis and medication.
Ethics and dissemination The project is approved by 
the Regional Ethics Committee, Norway (REC number 
2017/2150/REC south- east D). All papers will be published 
in open- access journals and results will be presented in 
national and international conferences.
Trial registration numbers ISRCTN11573246 and 
ISRCTN11891971.
INTRODUCTION
Attention- deficit/hyperactivity disorder 
(ADHD) is among the most common mental 
disorders in children and adolescents,1–4 and 
is often associated with problems into adult-
hood.5 ADHD is a persistent neurodevelop-
mental disorder characterised by symptoms of 
inattention and/or hyperactivity and impul-
sivity that are excessive for an individual’s age 
or overall development.6 7 ADHD is a strong 
risk factor for school drop- out,8 injuries,9 
comorbidity,10 self- harm and mortality,11–14 
contact with child welfare services,15 16 as well 
as lack of employment,17 18 later substance use 
disorders17 19–21 and criminality.22–24
Strengths and limitations of this study
 ► This study will use reliable and complete national 
registry data to study real- world effects of attention- 
deficit/hyperactivity disorder (ADHD) diagnosis and 
medication on long- term psychosocial outcomes 
highly relevant for patients, families and society at 
large.
 ► We use observed variations in rates of ADHD diag-
noses and medication between public sector child 
and adolescent psychiatric outpatient clinics for 
causal modelling, enabling empirical investigation of 
research questions which cannot be addressed in 
conventional randomised controlled trials for ethical 
and practical reasons.
 ► In Norway, ADHD in children and adolescents is al-
most exclusively diagnosed in public sector special-
ist services, which is covered by our registry data, 
ensuring representative data for the Norwegian gen-
eral population.
 ► The observed variation in ADHD diagnosis and med-
ication within Norway reflects most of the variation 
observed between countries, relevant to the external 
validity of the study.
 ► Whereas the strength of registry data as used in this 
study is related to data completeness and reliability, 
the weakness relates to validity and in some cases 
also data availability.
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Clinical treatment guidelines recommend a multimodal 
approach that combine psychosocial and pharmacolog-
ical treatment options.25 26 Behavioural intervention such 
as parent training is presently considered an important 
part of the treatment for patients with ADHD.27 While not 
proven to be effective in reducing core ADHD symptoms, 
evidence shows that it has positive effects on parenting 
and reduces oppositional and noncompliant behaviours 
in children, and may also lead to improvement in parent- 
child relationships as well as children’s emotional, social 
and academic functioning.
In the case of pharmacological treatment, on the other 
hand, several clinical trials have provided evidence of 
psychostimulants’ safety and efficacy in reducing ADHD 
symptoms in the short term.28 29 Short- term studies show 
that medication reduces symptoms in at least 75% of chil-
dren and adolescents with ADHD,30 suggesting that medi-
cation may be superior to both psychological interventions 
and no treatment.31 Evidence from a recent systematic 
review and network meta- analysis of 133 double- blind 
randomised controlled trials (RCTs) concluded that the 
first- choice medications for the short- term treatment of 
ADHD should be methylphenidate and amphetamines 
for children/adolescents and adults, respectively.29
While short- term effects of medication are estab-
lished (although with some discussions surrounding 
the evidence base),32 there are few studies on long- term 
effects of such treatment.29 Further, what general conclu-
sion to draw from the existing findings on this topic is 
still under discussion, as illustrated by a recent debate 
section in Journal of the American Academy of Child & Adoles-
cent Psychiatry.33–35 This debate illuminated that although 
several long- term studies indicate positive consequences 
of ADHD medication use, effect sizes are typically reduced 
compared with short- term results; additionally, in an even 
longer time perspective, it seems that the effectiveness 
of treatment- as- usual wanes and may not even be signif-
icant.35 From the opposing standpoint of the debate, 
however, it is proposed that the apparent lack of long- 
term benefits of medication is likely caused by insufficient 
monitoring and adjustment of treatment for patients 
followed up over long periods of time, and should not be 
used as a general argument against the effectiveness of 
medication in the treatment of ADHD.34
A promising source of long- term effect estimates 
to contribute to this debate is nationwide register 
studies.5 36 37 In recent years, register studies using quasi- 
experimental designs have shown that medication may 
reduce risk of unwanted outcomes associated with ADHD 
such as crime,38–41 substance abuse,42 injuries9 43 and 
motor vehicle accidents.44 However, as summarised in a 
recent review covering register- based studies on the effects 
of ADHD medication on a wide range of behavioural and 
neuropsychiatric outcomes, the available evidence even 
from register based pharmacoepidemiological studies on 
long- term effects of ADHD medication are still less clear 
than studies on short- term effects, and are subject to 
several limitations.37 As pointed out by these authors and 
others, more long- term studies that examine functional 
outcomes in real- world settings are needed.28 29 34 37 45
Over recent decades, there have been substantial 
increases in clinical diagnosis and pharmacological treat-
ment of ADHD in many countries,2 including North 
America,46 Europe,47 Australia48 and Asia.49 Recent 
systematic reviews and meta- analyses estimate that the 
global prevalence rate of ADHD in children and adoles-
cents is between 3.4%1 and 7.2%.50 It has been estimated 
that at least an additional 5% of children and adolescents 
have substantial difficulties with excessive and impairing 
levels of overactivity, inattention and impulsivity that are 
just below the threshold for diagnostic criteria.51 Some 
studies attribute the variation in prevalence estimates 
to social and cultural factors,52 while others downplay 
geographical location and argue for a methodological 
explanation.3
A retrospective study based on population- level data-
bases from 13 countries and 154.5 million individuals 
showed that prevalence of ADHD medication use in chil-
dren aged 3–18 years varied between 0.27% and 6.69% 
across included countries.53 Among the Nordic countries, 
the prescription prevalence has been estimated to range 
from 0.12% in Finland to 1.25% in Iceland.54 Further, 
large within- country variation in prescription rates has 
been reported in several countries, for example, the 
USA,55–57 Denmark,58 59 Sweden60 and Germany.61
Even within Norway, a country with a modest inequality 
and a universal healthcare system, there are substantial 
regional differences in diagnosis and medication.62 63 
For instance, the countywise rates for ADHD diagnosis in 
Norway at ages 6–12 vary between 1.7 % and 4.8 % for 
boys and between 0.4 % and 2.0 % for girls, and similar 
variation has been noted for medication rates.62 In total, 
80% of the children and adolescents diagnosed with 
ADHD fill one prescription for ADHD medication,62 and 
approximately 50% continue to collect prescriptions for 
more than 1 year.64 In addition to geographical variation 
in diagnosis and medication rates, studies have shown 
that being young relative to peers is a strong predictor 
for being diagnosed with ADHD in several countries.65 66 
A Norwegian chart review indicated that only 49% of all 
diagnoses were adequately documented.67
Internationally, the variation in ADHD diagnosis and 
medication rates have caused a debate with two opposing 
perspectives. On the one hand, there is a restrictive 
perspective characterised by concerns about poten-
tial overdiagnosis of ADHD, leading to medicalisation 
of normal behaviour,68 unnecessary stigma69 and side 
effects of pharmacological treatment70 that might not 
even be helpful in the presence of true ADHD. On the 
other hand, there is a liberal perspective distinguished by 
concerns about underdiagnosis and undertreatment,71 
which argues that increased rates of ADHD diagnosis and 
medication are due to improved recognition and under-
standing by professionals,72 73 broadened diagnostic defi-
nitions74 and methodological problems in the literature.2 
This perspective emphasises the importance of reducing 
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the risk of adverse outcomes associated with untreated 
ADHD, such as injuries,9 school drop- out8 and criminal 
behaviour.43
This debate may be reflected in clinical practice, where 
patients referred to specialist healthcare with suspicion of 
ADHD present with various degrees and compositions of 
symptoms (figure 1). Clinicians generally regard ADHD 
symptoms on a continuum. Although the diagnostic 
manuals define a symptomatic and functional cut- off 
for ADHD,75 diagnosis is inevitably based on a clinical 
judgement. This discretionary decision is likely to vary 
between clinicians,62 partly due to underlying restrictive 
or liberal perspectives. Figure 1 presents our theoretical 
model on clinicians’ consensus on diagnosis and medica-
tion by ADHD symptom load among patients in contact 
with child and adolescent psychiatric outpatient clinics. 
Clinicians will generally agree that patients with very few 
or no symptoms of ADHD should receive neither a diag-
nosis nor medication (left side of figure 1).76–78 On the 
opposite end of the continuum are patients with obvious 
ADHD symptoms, for whom most if not all clinicians will 
agree on ADHD diagnosis and medication (right side of 
figure 1).
The controversy on ADHD diagnosis and ADHD medi-
cation mostly relates to the middle area of the symptom 
distribution in figure 1, which includes patients with 
ambiguous symptoms, bordering on the threshold for 
diagnostic cut- off. These patients may be presenting with 
symptoms compatible also with other diagnoses or could 
be experiencing psychosocial stress that may produce 
ADHD- like symptoms, making an ADHD diagnosis diffi-
cult to establish.
In light of increasing ADHD diagnosis and medication 
rates in most Western countries, it is important to improve 
our knowledge on the effect of diagnosis among patients 
around the clinical threshold for diagnosis, as well as 
the effects of medication on long- term outcomes among 
patients. This is an important issue to address as it can 
inform the debate on underdiagnosis and overdiagnosis 
and medication. A pressing issue is whether patients with 
ambiguous ADHD symptoms benefit or not from being 
diagnosed. As pointed out by Owens,79 an ADHD diag-
nosis ‘… can bring beneficial pharmacological treatment 
and social supports, but it can also trigger negative social 
and psychological processes, as suggested by labelling 
theory’. Being diagnosed entails a set of at least three 
components that interact on long- term outcomes: (1) 
stigma (‘diagnosis labelling effects’),76 80–83 (2) medica-
tion and (3) psychosocial treatment. Owens79 finds that 
consistent with labelling theory (stigma), only those with 
severe prediagnosis symptoms seem to benefit from diag-
nosis and medication, while those with mild prediagnosis 
symptoms have worse outcomes compared with undiag-
nosed matches.
The key issue in identifying an effect of receiving a 
diagnosis is that diagnoses cannot be randomised to 
patients. Hence, we must either rely on epidemiological 
designs that precludes causal inference unless all poten-
tial confounding is statistically controlled, or we need to 
find sources of plausibly exogenous variation that can be 
used as a natural experiment. We believe the geograph-
ical variation in diagnosis and medication can be used 
as a natural experiment to identify causal effects of diag-
nosis and medication on long- term outcomes. There are 
several plausible explanations for geographical variation 
in diagnosis and medication rates on both the supply 
and demand side, including resources, capacity and 
patient mix. Nevertheless, a portion of the variation may 
be due to variation in clinician’s diagnosis and medica-
tion practice among public sector child and adolescent 
psychiatric outpatient clinics, commonly referred to as 
provider preference,84 which can lead to variation in 
diagnosis and prescription decisions for similar patients. 
Geographical variation may induce some random varia-
tion in treatment status for patients and may be used as an 
instrumental variable (IV) to obtain treatment effects.85 
Considering the regional differences in ADHD diagnosis 
and treatment, we expect that the child and adolescent 
outpatient clinics in Norway have different preferences. 
In single- provider universal access health systems, varia-
tion in health service provision that is not accounted for 
by differences in patient populations and symptom load is 
usually regarded as unwarranted and unwanted.86
The current research project aims to contribute to 
the existing knowledge on ADHD diagnosis and ADHD 
medication in several ways. Our project will employ 
Norwegian registry data to explore four main aims with 
corresponding work packages (WP):
WP1: The epidemiology of ADHD prognosis. The 
main aim of this WP is to describe the general long- term 
prognosis of ADHD compared with the general popula-
tion. This is in response to the typical parental concern: 
‘My child is diagnosed with ADHD, how will he/she do 
in life?’ By long term, we here mean years rather than 
months, including the important transition from child-
hood and adolescence to early adult life. We will examine 
the prognosis of patients diagnosed with ADHD in child 
Figure 1 Theoretical model on clinicians’ consensus on 
diagnosis and medication by ADHD symptom load among 
referred patient. ADHD, attention- deficit/hyperactivity 
disorder.
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and adolescent psychiatry (with and without medica-
tion). These will be compared with patients in child and 
adolescent psychiatry who received other diagnoses, 
or who received no diagnosis. We will also compare to 
the general population without contact with child and 
adolescent psychiatry. Measures of prognosis include 
registry data records of emergency care visits/injuries, 
comorbidity, contact with child welfare services, contact 
with adult psychiatric health services, education, employ-
ment and income, welfare dependency, crime, self- harm, 
suicide and mortality.
WP2: The ADHD variation controversy. This WP has 
two aims: first, we will describe the geographical variation 
in ADHD diagnosis and medication in Norway. We will 
describe this variation at the level of the catchment areas 
for child and adolescent psychiatric outpatient clinics in 
Norway. We will describe the variation in ADHD diagnosis 
as proportion of children and adolescents referred to 
these clinics and as proportion of children and adoles-
cents in the catchment area, and also in ADHD medica-
tion as proportion of diagnosed patients. Second, we aim 
to explain this variation by three strategies:
1. We will explore to what extent this variation in clinical 
practice can be attributed to catchment area charac-
teristics. Data on catchment areas will also be included 
in WP3 and WP4 as potential confounding variables.
2. Further, we will explore to what extent it can be at-
tributed to the variation in observed ADHD symptoms 
as observed in a nationwide health study of the general 
population.87 At an aggregated level, a strong positive 
association between the observed symptoms (as self- 
reported by mothers) and rates of diagnoses and med-
ication (as observed in registry data) will challenge the 
instrument planned for this study.
3. Finally, we will survey clinicians working at the about 
90 child and adolescent psychiatric outpatient clinics 
in Norway, exploring the variation in their attitudes 
and opinions towards ADHD diagnosis and medica-
tion. Specifically, we will explore if these attitudes and 
opinions vary on a continuum from restrictive to liber-
al. We will also explore if this variation in attitudes and 
opinions correlate at the aggregated level of the clin-
ics with observed rates of ADHD diagnosis and med-
ication (according to the registry data), and with the 
variation in ADHD symptoms (according to the health 
study87).
WP3: Long- term effects of receiving an ADHD diag-
nosis. The main aim of this WP is to examine if it makes 
any long- term difference for the prognosis of patients if 
they attend clinics with liberal or a restrictive practice on 
ADHD diagnosing. We assume that clear ADHD will be 
diagnosed at all clinics, and that clear non- ADHD patient 
will not receive the ADHD- diagnosis anywhere. Conse-
quently, this WP aims to analyse the effect of ADHD diag-
nosis for patients on the margin of receiving the diagnosis, 
who are most likely to be treated differently at clinics with 
a liberal vs restrictive approach to the diagnosis. We will 
identify causal effects of being diagnosed with ADHD 
among patients in contact with child and adolescent 
psychiatric outpatient clinics on long- term outcomes 
including emergency care visits/injuries, comorbidity, 
education, contact with child welfare services, contact 
with adult psychiatric health services, employment and 
income, welfare dependency, crime, self- harm, suicide 
and mortality.
WP4: Long- term effects of ADHD medication. The 
main aim of this WP is to examine if it makes any long- 
term difference for the prognosis of patients diagnosed 
with ADHD whether they attend a clinic with a liberal or 
restrictive ADHD medication practice. Not all patients 
who receive the ADHD diagnosis will be prescribed medi-
cation, and we assume that patients who are on the margin 
of receiving such treatment will be treated differently at 
clinics with a liberal versus restrictive approach. We will 
identify causal effects of initial ADHD medication among 
patients diagnosed with ADHD on long- term outcomes 
including emergency care visits/injuries, comorbidity, 
education, contact with child welfare services, contact 
with adult psychiatric health services, employment and 
income, welfare dependency, crime, self- harm, suicide 
and mortality.
Registry- based studies on effects of ADHD- medication 
that address limitations of RCTs, such as generalisability, 
follow- up time and less frequent psychosocial outcomes, 
is expanding.37 The main challenge of these studies 
is confounding, which several studies try to address 
by research designs such as within- subjects designs,37 
difference in differences9 and IVs.43 88 Our project’s 
original contribution lies in using two identification strat-
egies which have not previously been applied to evaluate 
effects of diagnosis nor medication on several included 
outcomes. There has only been conducted one IV anal-
ysis of ADHD medication effects on hospital contacts and 
criminal behaviour using Danish nationwide registry data 
and one IV study on ADHD medication effects on teens 
risk of sexual behaviour outcomes, substance abuse and 
injuries using Medicaid data.88
METHODS AND ANALYSIS
Project period
The project is funded by a grant from the Western Norway 
Regional Health Authority starting 1 January 2018 lasting 
6 years, and a grant from the Research Council of Norway 
lasting 4 years starting 1 November 2019. The project 
period may be extended with additional funding and for 
personnel- related reasons.
Design
Our project employs methods for descriptive analyses and 
causal inference.89 90 Our study draws on several linked 
Norwegian nationwide registries. Nordic registry data 
provide individual level data for the whole population,91 
and are only censored by migration and death.92 Our 
project has four WPs:
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WP1: the epidemiology of ADHD prognosis
This first work- package is conventional epidemiology, 
analysing outcomes (prognosis) in the ADHD popula-
tion compared with the general population. The aim is 
to provide general data on the prognosis of the ADHD 
population, employing all available outcomes. We will 
use survival analysis93 to examine time to event for our 
outcomes. In line with recent studies,94 we will account 
for possible competing risks to avoid overestimation of 
the cumulative incidence of our events of interest. We will 
also apply mixed- effects analysis, which is well suited and 
an established standard for individual- level longitudinal 
data with repeated observations.93 95
WP2: the ADHD variation controversy
This second WP will employ conventional statistics 
including scatter plots and regression models. Most anal-
yses will be performed on data aggregated to geograph-
ical regions (counties or finer) and (when data allows 
for this) to the about 90 child and adolescent psychiatric 
outpatient clinic catchment areas. To account for patient 
clustering and repeated observations over time, we will 
use standard generalised linear models with cluster- 
robust SEs and mixed- effects models.93 96
WP3 and WP4: long-term effects of receiving an ADHD 
diagnosis and ADHD medication
To identify the effect of ADHD diagnosis (WP3) and 
ADHD medication (WP4) on long- term outcomes, we will 
use child and adolescent psychiatric outpatient clinics’ 
catchment area variation in diagnosis and medication 
as IVs. IV is a common identification strategy in health 
services research97 that exploits the random variation 
induced in a treatment variable (here, ADHD diagnosis or 
ADHD medication prescription) by a plausibly exogenous 
(as- if random) event or process (ie, the instrument). The 
role of the instrument is to ‘isolate’ exogenous variation 
in the treatment, and hence to remove the endogenous 
(confounded) variation, so that the analysis only uses the 
exogenous variation to estimate the treatment effect.98 In 
this sense, IV analysis is a quasi- experimental approach. 
There is evidence to support that research designs with 
valid IVs can provide similar estimates as randomised 
experiments on the same research questions,97 99 100 
whereas more traditional observational studies without a 
credible source of exogenous variation often do not.98 100 
Our identification strategies exploit as- if random variation 
in providers’ preference to diagnose patients with ADHD 
and to prescribe ADHD medication43 88 across Norwegian 
public sector child and adolescent psychiatric outpatient 
clinics. The main idea behind provider preference- based 
instruments is that ‘…different providers or groups of 
providers have different preferences dictating how medi-
cations or medical procedures are used.’84 If the provider 
preference is associated with treatment, does not directly 
affect the outcome, and is not associated with unmea-
sured risk factors of the outcome, it may be used as an 
IV to consistently estimate the treatment effect.85 We will 
use two candidate provider preference instruments, illus-
trated in figure 2.
Preference-based IVs
It is plausible that a provider’s preference for diagnosing 
ADHD affects whether or not an individual is diagnosed 
with ADHD, while it is not associated with the outcomes 
of interest (ie, via paths other than affecting diagnosis) 
net of certain controls. We will use provider preference 
for ADHD diagnosis to identify the effect of diagnosis 
on long- term outcomes. Similarly, provider preference 
for ADHD medication likely affects whether or not a 
patient receives medication, while it is not associated 
with our outcomes of interest, net of certain controls. 
Provider preference for ADHD medication will be used 
to identify the effect of ADHD medication on long- term 
outcomes. Provider preferences for medication have 
become a well- established IV in epidemiology,101 as they 
are usually strongly associated with medication use and 
reduce covariate imbalance.102 Our IVs will be defined at 
the provider level (ie, the catchment area of child and 
adolescent psychiatric outpatient clinics), which may be 
stronger and more efficient compared with physician- 
level instruments.103 The (catchment) area definition of 
child and adolescent psychiatric outpatient clinics strikes 
a reasonable balance between methodological issues 
introduced by too large or too small area definitions.104
To our knowledge, provider- level preference for diag-
nosis62 63 is a novel candidate instrument, while provider 
Figure 2 Two sources of as- if randomisation. Quasi- experiment 1 is provider preference for ADHD diagnosis. Quasi- 
experiment 2 is provider preference for ADHD medication among those diagnosed with ADHD. ADHD, attention- deficit/
hyperactivity disorder.
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preference for ADHD medication has only been used in 
at least four prior studies,43 88 105 106 which do not cover 
all outcomes in our project. We illustrate the variation 
that will be used as provider preference instruments for 
the effects of diagnosis (WP3) and medication (WP4) at 
the county level in figure 3. Our eventual analysis will use 
preferences measured at the level of catchment areas of 
child and adolescent psychiatric outpatient clinics.
Although rates of diagnosis and medication follow each 
other closely, preliminary evidence on the county level 
indicates that they do not correlate perfectly, as shown in 
figures 3 and 4.
Setting of study and assessment of identification strategy
Preference- based instruments may lead to biased infer-
ences if the identifying assumptions are not met.107 The 
application of IV rests on a set of key assumptions that 
must be met to warrant a credible causal interpretation 
of estimates. Overall, an IV- strategy can be evaluated on 
a continuum from low to high credibility based on the 
underlying assumptions.108 The two main assumptions of 
IV are relevance and exclusion. Relevance can be tested 
statistically, while exclusion can only be partially tested 
and relies on justification derived from subject- matter 
knowledge. The instruments are likely to meet the rele-
vance assumptions as public sector child and adolescent 
psychiatric outpatient clinics are the only institutions in 
Norway that can diagnose ADHD and initiate pharmaco-
logical treatment of ADHD (aside from a small number 
of private practices), and the share of patients diagnosed 
with ADHD and medicated for ADHD varies considerably 
across areas.
We expect that the instrument meets the exclusion 
restriction in several respects. We expect provider pref-
erence for diagnosis and medication only to affect 
long- term outcomes through diagnosis and treatment 
decisions. Although patients in Norway are free to choose 
outpatient clinics, which opens the door to self- selection 
bias in principle, in practice, the vast majority of patients 
use the nearest child and adolescent psychiatric outpa-
tient clinic for convenience and because child and adoles-
cent psychiatric outpatient clinics are expected to deliver 
equal services of equal quality.109 There is no competitive 
market in this part of the health sector. Furthermore, it is 
unlikely that patients would sort in response to provider 
preferences, as the variation in rates of ADHD diag-
nosis and treatment are not common knowledge among 
patients or their parents. Consequently, children with 
similar ADHD symptoms are as- if randomly assigned to 
ADHD medication or no ADHD medication at a national 
level.
Next, we will control for the characteristics of the catch-
ment area and the patient mix of each provider that may 
partially explain variation in diagnosis and prescription 
practices. We have relied on existing research and expert 
knowledge in our assessment of relevant control variables 
and included variables in our data accordingly.110 In addi-
tion to our microlevel data, we construct a municipality- 
level data set from publicly available register data to further 
Figure 3 County variation in ADHD diagnosis and medication percent for children and adolescents between 10 and 19 years 
in Norway. ADHD as main diagnosis registered once or more times during 2009–2011. Registered diagnosis in NPR 2009–
2011 and registered filled ADHD prescription NorPD 2012. ADHD, attention- deficit/hyperactivity disorder; NorPD, Norwegian 
Prescription Database; NPR, Norwegian Patient Register; WP, work package.
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improve our adjustment for potential confounding. (Our 
list of potential confounders is presented in table 1). 
Exclusion is plausible due to the existence of large 
geographical variation in ADHD diagnosis and medica-
tion, net of demographic factors,43 62 111 which suggests 
that clinical practice varies for idiosyncratic reasons. As 
further validity assessment, we will analyse whether there 
is geographical variation in ADHD symptoms using the 
nationwide The Norwegian Mother and Child Cohort 
study (MoBa), and whether referral frequencies vary 
geographically using data from the Norwegian Patient 
Register.
Table 1 Potential confounders for facility- level instrumental variables
Confounder 
category
Potential confounders Covered Data source
Geographic Urban/rural Yes. Municipality data set and 




Race, education, income, age, 
insurance status, health status/
comorbid conditions, health 
behaviours
Insurance status is not likely an issue in 





Procedure volume, facility 
volume, clinical services offered, 
departments, teaching status, profit 
status, trauma designation, delivery 
system type, practice type
Although the sizes of the facilities vary, the 
provided services and the organisation of 
the facility are part of the same nationwide 
healthcare system and should be similar. 
Profit status is likely not an issue in 
Norwegian healthcare system.
Municipality data set and 




Receipt of other treatments We may adjust for contacts with 
health services for treatment and 
common prescriptions (eg, melatonin, 
antidepressants)
Microdata (table 2).
Table based on Garabedian et al.110
Figure 4 Scatterplot of ADHD diagnosis and medication among children and adolescents between 10 and 19 years by 
Norwegian counties. ADHD as main diagnosis registered once or more times during 2009–2011. Linear fitted line. Registered 
diagnosis in NPR 2009–2011 and registered filled ADHD prescription NorPD 2012. ADHD, attention- deficit/hyperactivity 
disorder; NorPD, Norwegian Prescription Database; NPR, Norwegian Patient Register.
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Triangulation and statistical methodology
Our assessment of causal effects relies on IV triangu-
lated with other methods based on other assumptions.112 
As pointed out by Matthay et al.113: ‘All methods involve 
untestable assumptions and trade- offs in precision and 
validity’ and there is seldom a ‘… clear justification for 
exclusive reliance on one method’. We will supplement 
our IV- analysis with mixed- effects models, propensity 
score matching, inverse- probability weighting and fixed- 
effects regression (for medication).96 These are also the 
methods we will base our analysis on if IV- conditions are 
not met. All analyses will be performed in Stata 16.1114 
and R.115
Data and study sample
Our data comprises one sample of patients and one 
sample of controls from the general population. The 
patient sample includes all persons between 5 and 18 years 
of age that had any contact (for any reason) with child 
and adolescent psychiatric outpatient clinics between 
2009 and 2011 (ie, birth cohorts 1991–2006). Children 
younger than 5 years are not included as few children are 
diagnosed with ADHD before age 5.43 The control sample 
is a random sample from the general population of equal 
size as the patient sample defined as individuals in Norway 
5–18 years old without reported contact (for any reason) 
with child and adolescent psychiatric outpatient clinics in 
2009–2011. The control sample is included to enable us 
to compare the prognosis among patients diagnosed with 
ADHD and patients in contact with child and adolescent 
psychiatric outpatient clinics to the general population.
As the project will examine outcomes that occur at 
different points over a life course (injuries, contact with 
child welfare services, contact with adult psychiatric 
health services, education, income, welfare dependency, 
comorbidity, crime, self- harm, suicide and mortality), we 
will receive data for 2009–2019 in 2020 and for 2020–2021 
in 2022. We have estimated that the patient sample with 
an equally sized control sample from the general popu-
lation (matched on age, gender and geography) will be 
approximately 200 000. All analyses are registry based. 
We combine data from a total of nine national registries, 
presented in table 2.
The registry data set will be supplemented with a 
municipality data set based on publicly available aggre-
gated administrative data. The municipalities will be 
grouped by child and adolescent psychiatric outpatient 
clinic catchment areas. The municipality data set serves 
two purposes: (1) examine associations between envi-
ronmental factors and geographical variation in ADHD 
diagnosis and prescription patterns and (2) account 
for population mix at child and adolescent psychiatric 
outpatient clinics in analyses. The municipality data set 
Table 2 Data from registries included in the project
National register Variables
Norwegian Patient Register Diagnoses (International Statistical Classification of Diseases and Related HealthProblems 
versjon 10 (ICD-10), all F- diagnoses by multiaxial coding), institution, in/out date, waiting time 
code, contact type, referral from institution, referral type, referral reason, injury (specialist 
care), injury severity, child welfare service involvement, child’s care situation, child’s 
environment, gender, age, patient catchment area
Control and Payment of Health 
Reimbursement Register
Injuries (emergency room) International Classification of Primary Care, Second edition (ICPC-
2) diagnoses (somatic: fracture, concussion, eye injuries, penetration, burn, poisoning, other 
injuries/ psychiatric: suicide attempt, hyperkinetic disorder, anorexia, schizophrenia)
Norwegian Cause of Death 
Registry
Death, cause of death (three categories: suicide, injury, other)
Norwegian Prescription 
Database
Psychostimulants for ADHD (Anatomical Therapeutic Chemical (ATC)- codes N06B, CO2, 
CO2A), melatonin (ATC- codes N05, N05B), antidepressants (ATC- code N06A), antiepileptics 
(ATC- code N03A), defined daily dose
The Central Penal and Police 
Register (Strasak)
Criminal charges (ten categories: property theft, other offences for profit, criminal damage, 
violence and maltreatment, sexual offences, drug and alcohol offences, public order and 
integrity violations, traffic offences, other offences)
The Central Population 
Register
Country of origin (world region), parents’ marital status, emigration
Municipality- State- Reporting Case type, who reported case, content of case, measure in child welfare services law, removal 
of custody, reason for administrative decision
Norwegian Education Database Highest completed level of education, parents’ educational level, ended high school education 
before completion (‘dropout’), average grade level for primary school, grades from high school 
completion, national test scores, order/conduct, absence
Income, tax and wealth register Income, work assessment allowance, social assistance, disability pension, unemployment 
assistance (‘dagpenger’), parents’ income
ADHD, attention- deficit/hyperactivity disorder.
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will include covariates for socioeconomic conditions 
(education, income, welfare recipiency), crime, income 
inequality, living conditions, health service utilisation and 
health service economic variables.
Patient and public involvement
Patients and public were not involved in the development 
of WPs or study design.
DISCUSSION
This project examines (1) the prognosis of ADHD, (2) 
within- country variation in ADHD diagnosis and medication 
rates by clinics’ catchment area, (3) causal effects of being 
diagnosed with ADHD on long- term outcomes and (4) 
causal effects of ADHD medication on long- term outcomes. 
The project relies on Norwegian nationwide register data 
and employs several methodological approaches, including 
survival analysis, mixed- effects models and IVs.
As outlined in the introduction, the debate concerning 
the long- term consequences of variation in diagnosis and 
medication of ADHD is far from settled. RCTs on ADHD 
may not adequately address the controversy on long- term 
effects of ADHD diagnosis or medication, as randomisation 
of these exposures on a large scale with long follow- up is 
infeasible. Causal inference from conventional epidemio-
logical designs is also generally implausible, due to unob-
served confounding. By combining rich nationwide register 
data with an IVs design, we are able to circumvent the 
shortcomings of both RCTs and conventional epidemiolog-
ical designs on these topics. Our approach aims to fill this 
knowledge gap by analysing effects of diagnosis and medi-
cation for children and adolescents on long- term outcomes.
In this sense, this project has merit to provide empirical 
evidence that neither RCTs nor conventional epidemio-
logical designs can address. First, there is to our knowl-
edge no trial randomising children to ADHD diagnosis. 
Our approach aims to fill this knowledge gap by instru-
ment variable analysis for children at the margin of an 
ADHD diagnosis. Second, most clinical trials of medica-
tion in ADHD to date has been conducted on children 
that clearly meet diagnostic criteria, whereas the variation 
and controversy is regarding children on the margin of 
receiving medication.
This project is the first detailed examination of within- 
country variation in ADHD diagnosis and ADHD medica-
tion by child and adolescent outpatient psychiatric clinics’ 
catchment areas, including possible associations with socio-
economic and demographic covariates. The project will be 
the first application of provider preference for ADHD diag-
nosis as an IV. The project will also be the first application 
of IVs to assess the effects of ADHD diagnosis and ADHD 
medication on several psychosocial outcomes.
The project is subject to the following limitations: 
Register data are limited to precollected data in registers, 
which also determine data selection and data quality.116 
Register data can be considered as the ‘administrator’s 
view of the world’ which affects data definitions and 
data collection practice, and often makes it challenging 
to understand data- generating processes.116 Moreover, 
register data are generally considered reliable, but the 
validity is important to assess due to complex data collec-
tion processes that varies between registers.92 117
ETHICS AND DISSEMINATION
Data management
The Norwegian Prescription Database (NorPD) will 
combine data from the different registries and replace 
the personal identification number with a project- specific 
number (pseudonymisation) before distributing data to 
the research group to protect the privacy of participants. 
NorPD will keep the linkage key between the personal 
identification number and the project- specific number. 
Data will be stored and analysed on a secure server at 
Haukeland University Hospital that only the PI and other 
preapproved researchers will have access to. To ensure 
the quality and reproducibility of our data management 
and statistical analyses, we will (1) cross- check each step 
in the data cleaning and preparation process and (2) 
document each step from the raw data to the final data 
sets and statistical analyses in version- controlled syntax 
and log- files. Missing data will be assessed, and we will 
consider strategies for multiple imputation.
Ethics approval and consent to participate
The project is approved by the Regional Committee for 
Medical and Health Research Ethics, Norway: REC South 
East, Committee D (REC number 2017/2150/REC south- 
east D). Due to the large number of participants, it is 
not feasible to obtain consent from all participants. The 
study has been evaluated by REC to be ‘of considerable 
importance to society’ and to ‘protect the integrity and 
welfare of the participants’. Based on the fulfilment of 
these criteria, the project has been exempted from the 
requirement of collecting informed consent from partici-
pants. The REC approval is given under the precondition 
that the project is conducted as described in the project 
application, protocol, communication and the adminis-
trative provisions in the Norwegian Health Research Act 
(‘Helseforskningsloven’) and appurtenant regulations.
Availability of data and materials
The data used in this project may not be made publicly 
available due to the sensitive nature of the data. Current 
approvals and regulations do not allow sharing these data. 
Due to general data protection regulations, restrictions in 
the ethics approval and restrictions by the registry owners, 
data may not be shared. We may share statistical code.
Dissemination
The publication strategy distinguishes between six types 
of publications planned from this project:
1. Preparatory publications: This includes the present 
protocol paper, trial registrations, systematic literature 
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reviews on subject matter issues regarding ADHD118 
and provider preference IV applications.119
2. WP1: The epidemiology of ADHD prognosis. We will 
utilise all data to describe common trajectories in 
ADHD. Multiple comparison groups will be employed 
including other patients referred to child and adoles-
cent psychiatry who got other diagnoses or no diag-
nosis, and also the general population. Outcomes are 
according to data as described in table 2.
3. WP2: The variation in ADHD diagnosis and treatment. 
We will describe in detail the geographical variation 
in ADHD diagnosis and medication, and also explore 
if characteristics of the catchment areas may explain 
some of the observed variation in clinical practice. We 
will publish results from the survey among clinicians 
at the public sector child and adolescent psychiatric 
outpatient clinics in Norway, exploring if their opin-
ions and attitudes to ADHD diagnosis and treatment 
vary from restrictive to liberal, and if this variation cor-
responds with the observed geographical variation in 
rates of ADHD diagnosis and medication. Further, we 
will publish results from the health survey, exploring if 
there is an association between rates of ADHD symp-
toms and ADHD diagnosis and medication.
4. WP3: Long- term effects of receiving an ADHD diag-
nosis for children on the margin of the diagnostic 
threshold. Publications on the effect of ADHD diag-
nosis among those referred to child and adolescent 
psychiatry on outcomes as described above. Outcomes 
according to data in table 2.
5. WP4: Long- term effects of ADHD medication. Pub-
lications on the effect of ADHD medication among 
those diagnosed with ADHD on outcomes as described 
above. Outcomes according to data in table 2.
6. Exploratory publications on hypotheses and topics be-
yond those here described. These may be subject to 
additional approvals from the ethics committee and 
the owners of the registries, eventually also an update 
of the Data Protection Impact Assessment.
We will follow International Committee of Medical 
Journal Editors Vancouver recommendations for author-
ship when publishing the papers. Most of our team 
members have significant experience in writing and 
publishing scientific papers, and we believe our multidis-
ciplinary team’s experience will serve as the main exper-
tise in writing the planned articles. We aim to publish with 
open access. Substantial amendments to our protocol will 
be reported to relevant parties through relevant channels.
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